Jacobs (NYSE: J) has been selected by Sanofi as the Engineering, Procurement, and Construction Management (EPCM) partner for a new insulin manufacturing facility in Frankfurt, Germany, according to an announcement from the Dallas-based company.
The project is aimed at modernizing insulin manufacturing and strengthening supply resilience.
Project Scope and Location
The new facility will be located alongside Sanofi's established insulin manufacturing campus in Frankfurt. Once complete, it will support the production of multiple insulin products and strengthen supply reliability, according to Jacobs.
Jacobs will provide integrated EPCM services spanning design, procurement, construction management, and commissioning. The company said it is building on its involvement during early project development, and it will leverage existing site infrastructure and advanced manufacturing technologies to deliver what it described as a state-of-the-art facility.
The project will incorporate advanced manufacturing systems that support efficient and reliable operations. To carry out the work, Jacobs will deploy an integrated team spanning engineering, procurement, project controls, construction management, commissioning, quality, and safety, delivering the project from design through startup.
A Legacy in Life Sciences
Jacobs Executive Vice President Sean Sommer tied the award to the company's history in the sector.
"Our life sciences legacy began in 1943, when our founder, Dr. Joe Jacobs, was part of the team that enabled the first commercial-scale production of penicillin," Sommer said. "More than 80 years later, we continue to deliver the advanced manufacturing facilities behind some of the world's most important therapies."
Trusted by Leading EPCs & Manufacturers
Find the Latest Pharmaceutical Plant Projects in Germany
Gain exclusive access to our industry-leading database of pharmaceutical plant opportunities with detailed project timelines and stakeholder information
Request Free Trial → Learn More →
No credit card Up-to-date coverage
Strengthening a Position in Pharmaceutical Manufacturing
Jacobs said the Sanofi award further strengthens its position as a leading solutions provider to global pharmaceutical and biotechnology manufacturers.
The company noted that earlier this year, Engineering News-Record (ENR) ranked Jacobs the No. 1 Pharmaceuticals Design Firm, a ranking Jacobs said reflects its leadership in delivering advanced pharmaceutical manufacturing and biomanufacturing facilities.
As an example of its work at scale, Jacobs pointed to its role providing EPCM services for FUJIFILM Biotechnologies' USD 3.2 billion Holly Springs campus, which it described as one of North America's largest biomanufacturing facilities.
The company said the project underscores its role in delivering complex life sciences investments at scale.
Jacobs' Footprint in Germany
The company also highlighted its broader presence in Germany, where it says it continues to deliver some of the country's most critical infrastructure and advanced manufacturing investments.
Recent work includes SuedLink, which Jacobs described as one of the world's largest underground high-voltage power cable projects; a framework with TransnetBW supporting Germany's grid expansion and energy transition; and thyssenkrupp Steel's major industrial decarbonization program.
With more than 300 employees across three offices in Germany, Jacobs said it provides integrated solutions spanning life sciences, energy, infrastructure, and advanced manufacturing, helping drive innovation, resilience, and long-term economic growth.
About Jacobs
Jacobs describes itself as a company "challenging today to reinvent tomorrow," delivering outcomes and solutions for the world's most complex challenges.
With approximately USD 12 billion in annual revenue and a team of approximately 47,000, the company provides end-to-end services in advanced manufacturing, cities and places, energy, environmental, life sciences, transportation, and water. Its services range from advisory and consulting, feasibility, planning, and design to program and lifecycle management.
How Germany's Chemical Giants Stay Ahead of the Project Curve
Germany's chemical sector is undergoing a profound transformation, driven by decarbonization mandates, reshoring of critical manufacturing, and record investments in sustainable practices and innovative technologies. Every new plant, retrofit, and logistics hub represents both opportunity and competition. The question is, are you hearing about these projects before your competitors do?
The Global Project Tracking (GPT) platform by Blackridge Research provides a crucial advantage in the German chemical sector. From early-stage announcements in chemical hubs to significant contract awards, the platform reveals actionable intelligence at every stage of the project lifecycle, enabling your team to connect with prospects at the most critical moments.
Whether you supply chemical raw materials, processing equipment, engineering services, or digital solutions, timely insights into Germany's chemical project pipeline can be the key to not just pursuing tenders but actively shaping them.
Upcoming Projects
Tender Notices
Contract Awards
Projects Under Construction
Completed Projects
Book a Free Demo of the Global Project Tracking (GPT) platform by Blackridge Research today and put the chemical project pipeline at your fingertips.
Leave a Comment
We love hearing from our readers and value your feedback. If you have any questions or comments about our content, feel free to leave a comment below.
We read every comment and do our best to respond to them all.